<DOC>
	<DOCNO>NCT02549014</DOCNO>
	<brief_summary>The purpose randomize , double-blind , placebo-controlled study evaluate safety , pharmacokinetics pharmacodynamics rise , single oral dos MK-1064 healthy , young , male participant . The primary pharmacokinetic hypothesis least one dose MK-1064 generally safe well tolerated produce average MK-1064 plasma concentration 0 4 hour ≥2.2 μM . Since early Phase I assessment MK-1064 human , study protocol allow modification outline dose , dose regimen and/or clinical laboratory procedure , require address study objective and/or ensure appropriate safety monitoring participant .</brief_summary>
	<brief_title>A Single Dose Study Safety , Pharmacokinetics Pharmacodynamics MK-1064 ( MK-1064-001 )</brief_title>
	<detailed_description>Two panel ( Panels A B ) , receive alternate single rise oral dos MK-1064/placebo ( i.e. , order administration Panel A 5 mg , Panel B 10 mg , Panel A 25 mg , Panel B 50 mg , continue alternate sequence ) . Following dose give treatment period , minimum 3 day elapse administration next schedule dose . After administration dose , safety tolerability review . The decision proceed next Panel/Period alternate sequence contingent acceptable safety tolerability data precede Panels/Periods .</detailed_description>
	<criteria>Body Mass Index ( BMI ) ≤31 kg/m^2 In good health base medical history , physical examination , vital sign measurement , laboratory safety test Nonsmoker use nicotine nicotinecontaining product least approximately 6 month Mentally legally incapacitate , significant emotional problem screen expect conduct study history clinically significant psychiatric disorder within last 10 year History persistent sleep abnormality ( include difficulty fall asleep , difficulty stay asleep ) last 3 month , history obstructive sleep apnea , restless legs syndrome , narcolepsy duration Participant experience poor quality sleep ( include difficulty fall asleep , difficulty stay asleep ) least 4 7 night per week past 30 day prior screen Participant work night shift able avoid night shift work minimum 1 week treatment period Participant travel across 3 time zone ( transmeridian travel ) last 2 week prior study Unwilling unable consume standard high fat breakfast History clinically significant endocrine , gastrointestinal , cardiovascular , hematological , hepatic , immunological , renal , respiratory , genitourinary abnormality diseases History seizure , epilepsy , stroke , peripheral neuropathy , clinically significant neurological disease cognitive impairment History cancer History cataplexy Participant unable refrain anticipates use medication , include prescription nonprescription drug herbal remedy , begin approximately 2 week prior administration initial dose study drug throughout study Participant consume &gt; 3 serving alcohol day Participant consume &gt; 6 caffeine serving day Participant major surgery , donate lose 1 unit blood ( approximately 500 mL ) participate another investigational study within 4 week prior screen History significant multiple and/or severe allergy anaphylactic reaction significant intolerability prescription nonprescription drug food Is currently regular user illicit drug history drug ( include alcohol ) abuse within 2 year screen Is regular user sedativehypnotic agent</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>December 2015</verification_date>
</DOC>